1,2-dichloroethane decreases expression EXP 6480464 ethylene dichloride results in decreased expression of CLSTN2 mRNA CTD PMID:28960355 1,2-dimethylhydrazine increases expression EXP 6480464 1, 2-Dimethylhydrazine results in increased expression of CLSTN2 mRNA CTD PMID:22206623 17beta-estradiol decreases expression ISO RGD:621151 6480464 Estradiol results in decreased expression of CLSTN2 mRNA CTD PMID:20068009 17beta-estradiol increases expression ISO RGD:621151 6480464 Estradiol results in increased expression of CLSTN2 mRNA CTD PMID:17010207 2,3,7,8-tetrachlorodibenzodioxine multiple interactions EXP 6480464 [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLSTN2 gene CTD PMID:21212295 2,3,7,8-tetrachlorodibenzodioxine decreases methylation EXP 6480464 Tetrachlorodibenzodioxin results in decreased methylation of CLSTN2 gene CTD PMID:21212295 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1350123 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA CTD PMID:28628672 4,4'-diaminodiphenylmethane decreases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of CLSTN2 mRNA CTD PMID:18648102 6-propyl-2-thiouracil decreases expression ISO RGD:621151 6480464 Propylthiouracil results in decreased expression of CLSTN2 mRNA CTD PMID:24780913 aflatoxin B1 decreases methylation ISO RGD:1350123 6480464 Aflatoxin B1 results in decreased methylation of CLSTN2 gene CTD PMID:27153756 aflatoxin B1 increases methylation ISO RGD:1350123 6480464 Aflatoxin B1 results in increased methylation of CLSTN2 exon CTD PMID:30157460 benzo[a]pyrene increases expression ISO RGD:621151 6480464 Benzoapyrene results in increased expression of CLSTN2 mRNA CTD PMID:21839799 benzo[a]pyrene increases methylation ISO RGD:1350123 6480464 Benzoapyrene results in increased methylation of CLSTN2 exon, Benzoapyrene results in increased methylation of CLSTN2 promoter CTD PMID:27901495 benzo[a]pyrene increases methylation EXP 6480464 Benzoapyrene results in increased methylation of CLSTN2 intron CTD PMID:27901495 benzo[a]pyrene multiple interactions EXP 6480464 [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA CTD PMID:27858113 benzo[b]fluoranthene multiple interactions EXP 6480464 [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA CTD PMID:27858113 benzo[e]pyrene increases methylation ISO RGD:1350123 6480464 benzoepyrene results in increased methylation of CLSTN2 exon CTD PMID:30157460 bisphenol A decreases expression ISO RGD:621151 6480464 bisphenol A results in decreased expression of CLSTN2 mRNA CTD PMID:25181051 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of CLSTN2 mRNA CTD PMID:30951980 bisphenol A increases expression ISO RGD:621151 6480464 bisphenol A results in increased expression of CLSTN2 mRNA CTD PMID:30816183 bisphenol A multiple interactions ISO RGD:1350123 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA CTD PMID:28628672 cefaloridine decreases expression ISO RGD:621151 6480464 Cephaloridine results in decreased expression of CLSTN2 mRNA CTD PMID:18500788 chrysene multiple interactions EXP 6480464 [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA CTD PMID:27858113 crocidolite asbestos decreases expression EXP 6480464 Asbestos, Crocidolite results in decreased expression of CLSTN2 mRNA CTD PMID:29279043 DDT decreases expression ISO RGD:621151 6480464 DDT results in decreased expression of CLSTN2 mRNA CTD PMID:30207508 dexamethasone multiple interactions ISO RGD:1350123 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA CTD PMID:28628672 diethylstilbestrol increases expression ISO RGD:621151 6480464 Diethylstilbestrol results in increased expression of CLSTN2 mRNA CTD PMID:17010207 dorsomorphin multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1350123 6480464 Doxorubicin results in decreased expression of CLSTN2 mRNA CTD PMID:29803840 endosulfan increases expression ISO RGD:621151 6480464 Endosulfan results in increased expression of CLSTN2 mRNA CTD PMID:29391264 ethanol affects splicing EXP 6480464 Ethanol affects the splicing of CLSTN2 mRNA CTD PMID:30319688 ethanol increases expression EXP 6480464 Ethanol results in increased expression of CLSTN2 mRNA CTD PMID:30319688 fonofos increases methylation ISO RGD:1350123 6480464 Fonofos results in increased methylation of CLSTN2 promoter CTD PMID:22847954 formaldehyde increases expression ISO RGD:1350123 6480464 Formaldehyde results in increased expression of CLSTN2 mRNA CTD PMID:28937961 GW 4064 decreases expression EXP 6480464 GW 4064 results in decreased expression of CLSTN2 mRNA CTD PMID:26655953 indometacin multiple interactions ISO RGD:1350123 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of CLSTN2 mRNA CTD PMID:28628672 lead(0) affects expression ISO RGD:1350123 6480464 Lead affects the expression of CLSTN2 mRNA CTD PMID:28903495 lead(2+) affects expression ISO RGD:1350123 6480464 Lead affects the expression of CLSTN2 mRNA CTD PMID:28903495 lipopolysaccharide decreases methylation EXP 6480464 Lipopolysaccharides results in decreased methylation of CLSTN2 gene CTD PMID:21212295 lipopolysaccharide multiple interactions EXP 6480464 [Tetrachlorodibenzodioxin co-treated with Lipopolysaccharides] results in decreased methylation of CLSTN2 gene CTD PMID:21212295 methapyrilene increases methylation ISO RGD:1350123 6480464 Methapyrilene results in increased methylation of CLSTN2 exon CTD PMID:30157460 methylmercury chloride increases expression ISO RGD:1350123 6480464 methylmercuric chloride results in increased expression of CLSTN2 mRNA CTD PMID:28001369 N-methyl-4-phenylpyridinium decreases expression ISO RGD:1350123 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of CLSTN2 mRNA CTD PMID:24810058 N-methylformamide increases expression EXP 6480464 methylformamide analog results in increased expression of CLSTN2 mRNA, methylformamide results in increased expression of CLSTN2 mRNA CTD PMID:17040096 nickel atom decreases expression ISO RGD:1350123 6480464 Nickel results in decreased expression of CLSTN2 mRNA CTD PMID:25583101 panobinostat multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of CLSTN2 mRNA CTD PMID:27188386 panobinostat increases expression ISO RGD:1350123 6480464 panobinostat results in increased expression of CLSTN2 mRNA CTD PMID:26272509 parathion increases methylation ISO RGD:1350123 6480464 Parathion results in increased methylation of CLSTN2 promoter CTD PMID:22847954 phenobarbital affects methylation EXP 6480464 Phenobarbital affects the methylation of CLSTN2 gene CTD PMID:19233941 phenylmercury acetate multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of CLSTN2 mRNA CTD PMID:27188386 pirinixic acid decreases expression EXP 6480464 pirinixic acid results in decreased expression of CLSTN2 mRNA CTD PMID:20813756 progesterone increases expression ISO RGD:621151 6480464 Progesterone results in increased expression of CLSTN2 mRNA CTD PMID:20726854 progesterone increases expression EXP 6480464 Progesterone results in increased expression of CLSTN2 mRNA CTD PMID:22238285 SB 431542 multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 sodium arsenite affects methylation ISO RGD:1350123 6480464 sodium arsenite affects the methylation of CLSTN2 gene CTD PMID:28589171 sodium arsenite increases expression ISO RGD:1350123 6480464 sodium arsenite results in increased expression of CLSTN2 mRNA CTD PMID:29301061 sulforaphane decreases expression EXP 6480464 sulforafan results in decreased expression of CLSTN2 mRNA CTD PMID:30529165 terbufos increases methylation ISO RGD:1350123 6480464 terbufos results in increased methylation of CLSTN2 promoter CTD PMID:22847954 Tesaglitazar decreases expression ISO RGD:621151 6480464 tesaglitazar results in decreased expression of CLSTN2 mRNA CTD PMID:21515302 tetraphene multiple interactions EXP 6480464 [Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA CTD PMID:27858113 titanium dioxide affects expression EXP 6480464 titanium dioxide affects the expression of CLSTN2 mRNA CTD PMID:23557971 titanium dioxide decreases expression EXP 6480464 titanium dioxide results in decreased expression of CLSTN2 mRNA CTD PMID:29264374 tremolite asbestos decreases expression EXP 6480464 tremolite results in decreased expression of CLSTN2 mRNA CTD PMID:29279043 trichostatin A increases expression ISO RGD:1350123 6480464 trichostatin A results in increased expression of CLSTN2 mRNA CTD PMID:26272509 trichostatin A multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of CLSTN2 mRNA CTD PMID:27188386 triclosan increases expression ISO RGD:1350123 6480464 Triclosan results in increased expression of CLSTN2 mRNA CTD PMID:30510588 troglitazone decreases expression ISO RGD:621151 6480464 troglitazone results in decreased expression of CLSTN2 mRNA CTD PMID:21515302 valproic acid affects expression ISO RGD:1350123 6480464 Valproic Acid affects the expression of CLSTN2 mRNA CTD PMID:25979313 valproic acid decreases expression ISO RGD:621151 6480464 Valproic Acid results in decreased expression of CLSTN2 mRNA CTD PMID:29427782 valproic acid multiple interactions ISO RGD:1350123 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of CLSTN2 mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1350123 6480464 Valproic Acid results in increased expression of CLSTN2 mRNA CTD PMID:23179753 more ... venlafaxine hydrochloride decreases expression ISO RGD:621151 6480464 Venlafaxine Hydrochloride results in decreased expression of CLSTN2 mRNA CTD PMID:25423262 vinclozolin affects expression ISO RGD:621151 6480464 vinclozolin affects the expression of CLSTN2 mRNA CTD PMID:19015723